

Radius Health, Inc. Investor Relations Department 950 Winter St, North ?Building 1st Floor North Building 1st Floo Waltham, MA 02451 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: RDUS Last Trade: 47.12 Trade Time: 4:00 PM ET Jun 23, 2017 Change: 0.00 (0.000%) Day Range N/A - N/A 52-Week Range 31.58 - 59.88 Volume N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a sciencedriven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical ... (more)

Stock Performance



Press Releases [View all]

Jun 4, 2017

Radius Presents Positive Data From A Fully
Enrolled Ongoing Phase I Study for
Investigational Drug Elacestrant (RAD1901)
at the 2017 American Society of Clinical
Oncology Annual Meeting (ASCO)

May 24, 2017

Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis

May 15, 2017

Radius Health Announces New Employment Inducement Grant

May 15, 2017

Radius Health Appoints Pharmaceutical

Executive Jose Carmona as Chief Financial

Officer

May 1, 2017

Radius Health Reports First Quarter 2017
Financial and Operating Results

Financials [View all]

Feb 24, 2017 Annual Report (10-K)

Apr 21, 2017
Proxy Statement (DEF 14A)

May 2, 2017 Quarterly Report (10-Q)

Nov 3, 2016 Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)